期刊文献+

应用噬菌体随机肽库技术筛选缓慢进展者HIV-1中和抗体模拟表位

Screening of HIV-1 neutralizing antibody mimotopes in slow progressor from phage display peptide library
原文传递
导出
摘要 目的以含有高水平HIV-1中和抗体的血浆为配体筛选HIV-1中和抗体模拟性抗原表位。方法为获取中和抗体识别的模拟表位,采用多轮感染外周血单个核细胞(PBMC)中和实验检测11例HIV感染缓慢进展者血浆中和抗体水平,利用噬菌体随机肽库对具有高水平中和抗体的血浆进行生物淘筛,ELISA方法鉴定阳性克隆。阳性克隆测序后与HIV Env gp41序列进行了同源性分析,应用Local Blast软件分析中和抗体模拟表位。结果3轮淘筛之后,得到22个阳性克隆。分析发现包括c8等12个可能的中和抗体模拟表位,位于gp41Ⅱ类功能区的C40对HIV-1血浆具有较高的抑制率。结论利用缓慢进展者血浆IgG抗体筛选噬菌体随机肽库,能够有效的获得多个HIV-1中和抗体相关抗原模拟表位。 Objective To screen mimetic HIV-1 neutralizing epitopes from plasma with high level neutralizing antibody, and to provide useful information for further study of the interaction between antigen and antibody. Methods In order to gain neutralizing antibody recognized mimotopes, we detected neutralizing antibodies levels of 11 HIV-1 infected slow progressors by PBMC-based neutralization assays. High-titer HIV-neutralizing antibodies from plasma of SPs was used as the ligand for biopanning by phage-displayed random peptide library. Positive phage clones was evaluated by ELISA, sequenced, and analyzed for homology to HIV-1 env by local BLAST to deduce the neutralizing peptide. Results Twenty-two clones were obtained consistent with requirement through three rounds biopanning. After comparison analysis, twelve clones include C8 were obtained as mimotopes of neutralizing antibody, C40 located in gp41 Ⅱ cluster with the highest titer by inhibition ratio may be as neutralizing epitope. Conclusion By the use of IgG antibodies from SPs to screen the phage random polypeptide library, one can acquire multiple phage mimetic peptides of HIV related antigen epitope.
出处 《中华检验医学杂志》 CAS CSCD 北大核心 2012年第9期838-842,共5页 Chinese Journal of Laboratory Medicine
基金 国家科技重大专项课题资助项目(2012ZX10001006) 国家自然科学基金资助项目(30901274)
关键词 HIV-1 表位 肽库 HIV感染 中和抗体 HIV-1 Epitopes Peptide library HIV infections Antibodies, neutralizing
  • 相关文献

参考文献11

  • 1Mufioz A, Kirby A J, He YD, et al. Long-term survivors with HIV-1 infection: incubation period and longitudinal patterns of CD4 + lymphocytes. J Acquir Immune Defic Syndr Hum Retrovirol, 1995, 8:496-505.
  • 2Scott JK, Smith GP. Searching for peptide ligands with an epitope library. Science, 1990,249:386-390.
  • 3Charles-Niflo C, Pedroza-Roldan C, Viveros M, et al. Variable epitope libraries: New vaccine immunogens capable of inducing broad human immunodeficiency virus type 1-neutralizing antibody response. Vaccine, 2011,29:5313-5321.
  • 4Huang JH, Yang HW, Liu S, et al. The mechanism by which molecules containing the H1V gp4l core-binding motif HXXNPF inhibit HIV-1 envelope glycoprotein-mediated syncytium formation. Biochem J, 2007, 403:565-571.
  • 5Frey G, Chert J, Rits-Volloch S, et al. Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non- neutralizing antibodies. Nat Struct Mol Biol, 2010, 17:1486- 1491.
  • 6Enshell-Seijffers D, Smelyanski L, Vardinon N, et al. Dissection of the humoral immune response toward an immunodominantepitope of HIV : a model for the analysis of antibody diversity in HIV + individuals. FASEB J, 2001, 15:2112-2120.
  • 7Zhang MY, Choudhry V, Sidorov IA, et al. Selection of a novel gp41-specifie HIV-1 neutralizing human antibody by competitive antigen panning. J Immunol Methods, 2006, 317:21-30.
  • 8张晓丽,韩晓旭,代娣,王哲,包名家,张子宁,徐东兵,耿文清,尚红.中国HIV/AIDS患者保守表位的2F5抗体与疾病进展关系[J].中华微生物学和免疫学杂志,2009,29(10):930-933. 被引量:1
  • 9Pantophlet R, Wilson IA, Burton DR. Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gpl20 as novel antigens for HIV vaccine design. J Virol, 2003, 77: 5889-5901.
  • 10Liu S, Lu H, Niu J, et al. Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gpl20. J Biol Chem, 2005, 280 : 11259-11273.

二级参考文献11

  • 1Xu W,Smith-Franklin BA,Li PL,et al.Potent neutralization of primary human immunodeficiency virus clade C isolates with a synergistic combination of human monoclenal antibodies raised against clade B.J Hum Virol,2001,4(2):55-61.
  • 2Joos B,Trkola A,Kuster H,et al.Long-term multiple-dose pharmacokinetics of human mnoclonal antibodies(MAbs)against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12)and gp41(MAbs 4E10 and 2F5).Antimicrob Agents Chemother,2006,50(5):1773-1779.
  • 3Stiegler G,Kunert R,Purtscher M,et al.A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency vires type 1.MDS Res Hum Retroviruses,2001,17(18):1757-1765.
  • 4Ofek G,Tang M,Sambor A,et al.Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope.J Virol,2004,78(19):10724-10737.
  • 5Alam SM,McAdams M,Boren D,et al.The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoeional antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes.J Immunol,2007,178(7):4424-4435.
  • 6Haynes BF,Fleming J,St Clair EW,et al.Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.Science,2005,308(5730):1906-1908.
  • 7McGanghey GB,Barbato G,Bianchi E,et al.Progress towards the development of a HIV-1 gp41-directed vaccine.Curr HIV Res,2004,2(2):193-204.
  • 8Srisurapanon S,Louisirirotchanakul S,Sumransurp K,et al.Binding antibody to neutralizing epitope sp41 in HIV-1 subtype CRF 01_AE infection related to stage of disease.Southeast Asian J Trop Med Public Health,2005,36(1):221-227.
  • 9Chen YH,Dierieh MP.Identification of a second site in HIV-1 gp41 mediating binding to cells.Immunol Lett,1996,52(2-3):153-156.
  • 10Braibant M,Brunet S,Cestaoiola D,et al.Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term nonprogressors:prevalence and association with neutralizing activity.AIDS,2006,20(15):1923-1930.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部